Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Purple Biotech (PPBT) Receivables - Other (2016 - 2024)

Purple Biotech has reported Receivables - Other over the past 3 years, most recently at $6000.0 for Q4 2021.

  • Quarterly Receivables - Other changed N/A to $6000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $6000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $6000.0 for FY2021, N/A changed from the prior year.
  • Receivables - Other was $6000.0 for Q4 2021 at Purple Biotech, down from $590000.0 in the prior quarter.
  • Over five years, Receivables - Other peaked at $762000.0 in Q2 2017 and troughed at $6000.0 in Q4 2021.